Biopharma industry lobbies for tax breaks related to US-based manufacturing

The business-friendly tax reform enacted in 2017, under the watch of former President Donald Trump, allowed some of the pharma industry’s top companies to slash much of their tax burden.

Six years later, the industry is working to gain another edge, The Financial Times reports. Specifically, the industry is targeting subsidies and tax breaks that could become available with an executive order President Joe Biden signed in September to advance manufacturing innovation in the United States.